Source comparison
Tesamorelin vs Growth Hormone Replacement Therapy
An important distinction in the research literature separates tesamorelin vs growth hormone replacement therapy. Direct GH replacement — using recombinant human growth hormone (rhGH) — has also been studied for visceral fat reduction and does produce meaningfu
This comparison does not assign a generated winner or score.
- An important distinction in the research literature separates tesamorelin vs growth hormone replacement therapy. Direct GH replacement — using recombinant human growth hormone (rhGH) — has also been studied for visceral fat reduction and does produce meaningful reductions in VAT. However, rhGH administration produces supraphysiological GH spikes that bypass the normal pituitary feedback mechanisms, resulting in a higher frequency and severity of adverse effects including glucose intolerance, fluid retention, and arthralgia compared to the pulsatile, physiologically regulated GH release that tesamorelin induces.
- Tesamorelin’s GHRH receptor agonist approach preserves the natural negative feedback loop: as GH and IGF-1 levels rise following tesamorelin stimulation, they suppress further GHRH receptor sensitivity, preventing runaway GH elevation. This self-regulating mechanism is considered an important safety advantage of the GHRH analogue approach over direct GH replacement and is one of the reasons tesamorelin demonstrates a more favourable tolerability profile than rhGH in head-to-head mechanistic comparisons.